MedImmune opens new R&D unit in UK
MedImmune, a unit of Anglo-Swedish drug major AstraZeneca, has opened a new, biologics R&D facility in Cambridge, UK. The Aaron Klug Building is an expansion of MedImmune's existing Granta Park site.
According to the firm, the 92,000-square-foot facility contains state-of-the-art laboratories and provides MedImmune with capacity to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals.
The expansion forms a key part of MedImmune's growth strategy. Following its acquisition by AstraZeneca in June 2007, the firm was consolidated with the former Cambridge Antibody Technology business, along with other areas of biological research being conducted elsewhere within AstraZeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze